Clinical Trial Update: Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of an estrogen receptor beta agonist (Eviendep) for recurrent colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Eviendep (Estrogen receptor beta agonist)

Snippet

Sponsor: CM&D Pharma Limited | Conditions: Adenocarcinoma of Colon Recurrent | Phase 1, Phase 2 | Status: COMPLETED